Earnings ·
Citius Oncology reported fiscal third quarter results ending June 30, 2026, generating $1.5 million in revenue for the…
CTORCitius Oncology, Inc.
Citius Oncology reported fiscal third quarter results ending June 30, 2026, generating $1.5 million in revenue for the quarter and $7.1 million for the first nine months of fiscal 2026, compared to zero in the prior year period. The company recorded a net loss of $8.9 million, or $(0.08) per share, for the quarter, driven by a $30.7 million general and administrative expense total that included a $19.7 million one-time CMO contract cancellation charge. Cash and cash equivalents stood at $16.6 million as of June 30, 2026, following approximately $9.7 million in net proceeds from warrant exercises and the funding of a $10.0 million tranche under a senior secured term loan facility. Institutional demand for its product LYMPHIR accelerated, with vial orders growing 31% sequentially to 926 units and 44 institutions now ordering the therapy. Citius Oncology is an oncology-focused biopharmaceutical company developing and commercializing targeted therapies.